Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Famotidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | POU5F1 | Q01860 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.67 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.67 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11389410 | 0.94 | HRH2 (0.62) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11380937 | 0.90 | HRH2 (0.63) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL10935664 | 0.88 | HRH2 (0.69) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11382761 | 0.87 | HRH2 (0.60) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11393006 | 0.86 | HRH2 (0.58) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL23804965 | 0.85 | HRH2 (0.74) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL23804963 | 0.85 | HRH2 (0.74) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL10863148 | 0.85 | HRH2 (0.59) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11378486 | 0.84 | CA2 (0.54) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11246474 | 0.84 | HRH2 (0.60) | HRH2SLC22A2CA12SLC22A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021183259-A1 | FAMOTIDINE AND FAMOTIDINE ANALOGS FOR CORONA VIRUS TREATMENT | Nanopharmaceutics, Inc. (US) | 2021-09-16 | — | — | WO | claimed |
| EP-0277900-A2 | H2-Receptor antagonist compounds | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1988-08-10 | — | — | EP | claimed |
| US-4283408-A | Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-08-11 | — | — | US | claimed |
| JP-56055383-A | — | — | None | — | — | JP | disclosed |
| JP-58103312-A | — | — | None | — | — | JP | disclosed |
| US-20260097023-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND FAMOTIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN AND/OR UPSET STOMACH | SCHABAR RES ASSOCIATES LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12514846-B2 | Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach | SCHABAR RESEARCH ASSOCIATES LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-12053457-B2 | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn | SCHABAR RESEARCH ASSOCIATES LLC (US) | 2024-08-06 | — | — | US | disclosed |
| US-12048690-B2 | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn | SCHABAR RESEARCH ASSOCIATES LLC (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117534630-A | Method for refining high-purity famotidine to prepare B crystal form | 重庆世森医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20240041861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS | NED BIOSYSTEMS INC (US) | 2024-02-08 | — | — | US | disclosed |
| EP-0297019-B1 | FAMOTIDINE POLYMORPHIC FORM AND PREPARATION THEREOF | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1991-10-30 | — | — | EP | disclosed |
| US-5021582-A | Acidifying alcoholic suspension, adding organic base, heating, diluting with chlorinated hydrrocarbon, cooling, filtering | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1991-06-04 | — | — | US | disclosed |
| EP-0322335-A1 | New-quanidino-thiazol compounds, their preparation, and use as intermediates of famotidine process | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1989-06-28 | — | — | EP | disclosed |
| US-4609737-A | DIHALOACETONE AND AMIDINOTHIOUREA | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-09-02 | — | — | US | disclosed |
| US-4562261-A | 2-Guanidinothiazoline compounds, and process for preparing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
| US-4497810-A | Thiatriazine dioxides as gastric anti-secretory agents | MERCK & CO., INC. (US) | 1985-02-05 | — | — | US | disclosed |
| JP-S58103312-A | AQUEOUS SOLUTION FOR INJECTION OF HARDLY SOLUBLE DRUG AND ITS PREPARATION | YAMANOUCHI PHARMACEUT CO LTD | 1983-06-20 | — | — | JP | disclosed |
| US-4283408-A | Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-08-11 | — | — | US | disclosed |
| JP-S5655383-A | AMIZINE DERIVATIVE AND ITS PREPARATION | YAMANOUCHI PHARMACEUT CO LTD | 1981-05-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097023-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND FAMOTIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN AND/OR UPSET STOMACH | SI, TNNC1, SLC10A2 | HRH2 10/4885SLC22A2 722/4885CA12 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.